A Phase III Randomised, Double-Blind, Placebo-Controlled, Multicentre Study of Durvalumab in Combination with Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib in Newly Diagnosed Advanced Ovarian Cancer Patients (DUO-O).

This study is looking for women who have recently been diagnosed with certain types of advanced cancer: specifically, high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer. "High-grade" means the cancer cells look more abnormal under a microscope and might grow faster.

To be considered for this study, you must be at least 18 years old. As the cancers being studied are specific to female anatomy, participants must be female.

There are other specific medical requirements that your doctor would check to make sure the study treatments are safe and suitable for you. This often includes things like your general health, how well your organs are working, and if you have certain other medical conditions.

If you join this study, you would first have a series of checks to confirm you're eligible. Once enrolled, you'd receive your assigned treatment, which could involve a combination of drugs given through an IV (into a vein) and tablets. This treatment would be given in cycles, meaning you'd have periods of treatment followed by breaks.

You would have regular visits to the clinic for medical check-ups, blood tests, and scans to monitor your health and how the treatment is working. These visits might be frequent initially and then become less often over time. If you receive maintenance treatment, this would continue after the initial chemotherapy period.

The total duration of your participation would involve the treatment period itself and then a long-term follow-up. This follow-up involves occasional checks, even after you've finished taking the study drugs, to track your progress over many years. You might be asked to fill out questionnaires about how you're feeling to help us understand your quality of life during treatment.